Jul 16, 2026, 3:00 AM ETInterview

Leading Cancer Researcher: They’re Ignoring My Research

Professor Thomas Seyfried posits that cancer is fundamentally a metabolic disorder originating from damage to the mitochondria, rather than a primary genetic disease caused by nuclear DNA mutations.
This theory, rooted in the work of Otto Warburg (1920s-1940s), asserts that all chronic diseases, including cancer, result from impaired oxidative phosphorylation within this organelle.
When mitochondrial efficiency is chronically compromised, cells revert to ancient, inefficient fermentation pathways (glycolysis and glutaminolysis) to produce ATP, leading to dysregulated cell growth.
Every cancer cell examined to date exhibits structural and functional defects in mitochondria, such as missing cristae or "ghost mitochondria," preventing them from utilizing oxygen efficiently.
Genetic mutations associated with cancer (e.g., BRCA1) are described as secondary risk factors that primarily function by reducing mitochondrial efficiency, rather than being 100% penetrant causes.
The "Oncogenic Paradox," originally noted by Albert Szent-Györgyi, is resolved by identifying the common mechanism: diverse agents (carcinogens, viruses, inflammation, hypoxia) all converge on damaging mitochondrial energy production.

Chronic damage to mitochondria is driven by a modern environment characterized by highly processed carbohydrates, physical inactivity, emotional stress, and poor sleep habits.
Specific environmental toxins identified as mitochondrial carcinogens include microplastics, "forever chemicals" (PFOA/PFAS), glyphosate, arsenic, cadmium, and synthetic pesticides.
Intermittent hypoxia, such as that caused by sleep apnea, forces cells to produce Reactive Oxygen Species (ROS), which damage mitochondrial membranes and trigger compensatory fermentation.
The comparison between wild wolves (rare cancer) and domestic dogs (cancer is the #1 killer) illustrates the impact of modern lifestyle: inactivity, processed diets, and obesity versus natural movement and whole foods.
Cancer incidence correlates strongly with high-income nations (e.g., US, Australia, NZ) and low-income nations with traditional lifestyles (e.g., Nepal, Gambia, Niger), attributing the disparity to environmental and dietary exposures rather than genetics alone.
The National Cancer Institute's current website description of cancer as a genetic disease is challenged by data showing mutations in driver genes exist in healthy "wild-type" cells without dysregulated growth.

Seyfried developed the Glucose-Ketone Index (GKI) as a quantitative biomarker to assess mitochondrial health and the risk of chronic disease.
The GKI is calculated by dividing blood glucose (converted to mmol/L) by blood ketone levels (mmol/L); a lower ratio indicates a healthier, more efficient metabolic state.
Zone of Prevention (Yellow/Green Zones): GKI values roughly between 0.9 and 3.0 are associated with the metabolic state of Paleolithic humans, where cancer and chronic disease incidence are historically low.
Zone of Risk (Red Zone): GKI values of 15.0 or higher (e.g., glucose ~90, ketones ~0.4) indicate a high-probability environment for chronic disease, driven by high carbohydrate intake and low ketone levels.
Patients can self-monitor using continuous glucose monitors (CGMs) and finger-prick ketone meters (e.g., Keto Mojo) to track their metabolic state in real-time.
Actionable prevention strategies include avoiding ultra-processed carbohydrates, reducing emotional stress, ensuring adequate sleep, and engaging in regular physical activity to maintain mitochondrial integrity.

Cancer cells are unable to burn ketone bodies because they require a structurally intact mitochondria to do so; they are "stuck" fermenting glucose and glutamine.
Inducing nutritional ketosis (raising ketones, lowering glucose) effectively starves tumor cells of their primary fuels while providing healthy cells with an efficient energy source.
This metabolic shift acts as a "metabolic vehicle" that enhances the efficacy of standard therapies (chemotherapy, radiation, immunotherapy) by allowing for lower, less toxic dosages.
Standard treatments like chemotherapy often force healthy patients into the "red zone" (stress, high glucose) to repair DNA damage, whereas ketosis protects healthy cells and removes the metabolic shield (lactic/succinic acid) protecting tumors.
The "Press-Pulse" therapeutic strategy involves "pressing" the tumor with metabolic therapy to restrict glucose and glutamine, followed by a "pulse" of targeted drugs (e.g., m-bendazole) to kill glutamine-dependent metastatic cells.
Case studies, such as the 10-year survival of a glioblastoma patient using only metabolic therapy and the use of high-dose chemo at low doses in pancreatic cancer, demonstrate the potential to extend life significantly beyond standard projections.
Metabolic therapy can also be effective in treating metastatic cancer, as hybrid tumor-macrophage cells driving metastasis are highly dependent on glutamine and glucose.

Mainstream oncology largely rejects metabolic approaches due to adherence to the somatic mutation theory, fear of cachexia (muscle wasting), and a lack of training in mitochondrial biochemistry.
Institutional barriers include the high cost of multi-center clinical trials required for dietary interventions and the profitability of a "sickness-based" medical model.
Seyfried is establishing the MORE Alliance (Metabolic Oncology Research and Education) to bring together clinicians, researchers, and patients to standardize and advance this therapeutic protocol.
Proposed government-level policy changes include massive education campaigns, subsidizing healthy foods to eliminate "food deserts," banning carcinogenic chemicals, and improving water filtration.
The speaker emphasizes that the goal is not to eliminate all conventional drugs but to utilize them more effectively within a metabolic context to reduce toxicity and extend survival.
Patients are encouraged to self-advocate by understanding the GKI, consulting with knowledgeable integrative oncologists, and potentially supporting private foundations that fund this specific research (e.g., Travis Christopherson's foundation).

Individuals can calculate their personal GKI by measuring fasting glucose and ketone levels; the goal is to maintain a low GKI (preferably under 3.0 for prevention, lower for active management).
Dietary interventions should focus on calorie-restricted Mediterranean, Carnivore, or ketogenic diets rich in healthy fats (avocado, olive oil, fatty fish) and low in processed sugars.
Intermittent fasting protocols are recommended to lower insulin and IGF-1 levels, triggering autophagy and further reducing tumor growth drivers.
Patients should be advised to avoid high-carbohydrate meal replacement shakes during treatment, as these can inadvertently feed tumors.
Those currently undergoing standard treatment should discuss the potential benefits of combining their regimen with metabolic therapy to enhance drug efficacy and reduce side effects.
The field is moving toward "precision metabolic medicine," where therapy is tailored to an individual's specific metabolic profile and GKI rather than a one-size-fits-all approach.